Fig. 2
From: Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis
Association of PDAC CS-CTC with clinical parameters. A Frequency of CTC-positivity (≥ 1 CTC detected) in DLA products according to the metastatic stage; B Normalized CS-CTC-concentration in DLA samples according to the metastatic stage; C-D OS according to status of DLA CS-CTC (n = 60, CTC/~70mL) in green/red compared to PB CS-CTC (n = 58, CTC/7.5mL blood) in grey. C Cutoff for CTC positivity: ≥1 CTC; D Cutoff for CTC positivity: ≥3 CTC; E OS according to the CTC-status separated by metastatic stage in DLA products (optimal cutoffs: M0 = 3CTC/~70mL blood; M1 = 23CTC/~70mL blood, see Additional File 1, Supplementary Fig. 4); F ROC curves and corresponding AUC values for the top 10 DLA CS-CTC cutoffs normalized to ~ 70mL of blood. These cutoffs were selected based on their combined highest hazard ratio and AUC value in the DLA cohort of 60 PDAC patients (ref: reference); G Parameters for all significant (p < 0.05) DLA CS-CTCs cutoff values calculated in the cohort of 60 PDAC patients (Cutoff: CTCs/~70mL); H OS according to CS-CTC status (≥ 1CTC/7.5mL blood) in PB pooled HE/DU-PB cohorts separated by metastatic stage (M0 vs. M1)